

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

Two potential equality issues were highlighted:

- | |
|---|
| <ul style="list-style-type: none">• A stakeholder welcomed the inclusion of Black men in the trial and noted that black men represented around 10% of the total trial population.• Darolutamide (oral therapy) could allow some people unsuitable for other potential treatments to be appropriately managed |
|---|

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

The committee will consider any relevant equality issues when it makes recommendations.

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No	

Approved by Associate Director (name):Richard
Diaz.....
2025

Date: 19 March